PBYI - Puma Bio up 6% after reporting neratinib data in lung cancer

Puma Biotechnology (PBYI) perks up 6% after presenting interim results from the ongoing SUMMIT trial of neratinib in the cohort of metastatic non-small cell lung cancer patients with epidermal growth factor exon 18 mutations.The interim efficacy results showed that for the 10 evaluable patients, 6 patients (60%) experienced a partial response, including 4 patients (40%) with a confirmed partial response.8 patients (80%) experienced clinical benefit (defined as confirmed complete/partial response or stable disease for at least 16 weeks).The median duration of response was 7.5 months and the median progression-free survival was 9.1 months.The success criteria for both the 1st stage and the 2nd stage of the Simon’s 2-stage design were met and enrollment in the 2nd stage of this cohort continues. No patients required a dose or reduction, hospitalization or permanently discontinued neratinib due to diarrhea.The data were presented in an oral discussion at the 2020 World Conference on Lung Cancer.

For further details see:

Puma Bio up 6% after reporting neratinib data in lung cancer